Kinetic bactericidal activity of telithromycin, azithromycin and clarithromycin against respiratory pathogens

APMIS

Volumn 113, Issue 10, 2005, Pages 655-63

  Drago, Lorenzo ^a   De Vecchi, E ^a   Nicola, L ^a   Legnani, D ^b   Gismondo, M R ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Haemophilus influenzae; Macrolides; Moraxella catarrhalis; Streptococci; Telithromycin

Indexed keywords

AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; CLINDAMYCIN; ERYTHROMYCIN; MACROLIDE; TELITHROMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERICIDAL ACTIVITY; BETA HEMOLYTIC STREPTOCOCCUS; DRUG SENSITIVITY; HAEMOPHILUS INFLUENZAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 28844462823     PISSN: 09034641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0463.2005.apm_195.x     Document Type: Article

References (24)

1. Baquero F, Barrett JF, Courvalin P, Morissey I, Piddock L, Novick WL. Epidemiology and mechanism of resistance among respiratory tract pathogens. Clin Microbiol Infect 1998;4(Suppl 2):19-26.
2. Sethi S. Infectious exacerbations of chronic bronchitis: diagnosis and management. J Antimicrob Chemother 1999;43(Suppl A):97-105.
3. Honeybourne D. Community-acquired pneumonia in ambulatory patients: relative importance of atypical pathogens. Int J Antimicrob Agents 2001;18(Suppl 1):S57-61.
4. Schito GC, Marchese A, Elkharrat D, Farrel DJ; PROTEKT Study Group. Comparative activity of telithromycin against macrolide-resistant isolates of Streptococcus pneumoniae: results of two years of the PROTEKT surveillance study. J Chemother 2004;16:13-22.
5. Hoban DJ, Doern GV, Fluit AC, Roussel-Devallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001;32(Suppl 2):S8-S31.
6. Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ; CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 2003;47:1875-81.
7. Canton R, Loza E, Morosini MI, Baquero F. Antimicrobial resistance amongst isolates of Streptococcus pyogenes and Staphylococcus aureus in the PROJEKT antimicrobial surveillance programme during 1999-2000. J Antimicrob Chemother 2002;50(Suppl S1):9-24.
8. Montanari MP, Mingoia M, Giovanetti E, Varaldo PE. Differentiation of resistance phenotypes among erythromycin-resistant pneumococci. J Clin Microbiol 2001;39:1311-5.
9. Zhanel GG, Walters M, Noreddin A, Vercaigne LM, Wierzbowski A, Embil JM, et al. The ketolides: a critical review. Drugs 2002;62:1771-804.
10. Leclercq R. Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001;48(Suppl T1):9-23.
11. Douthwaite S. Structure-activity relationships of ketolides vs. macrolides. Clin Microbiol Infect 2001;7(Suppl 3):11-7.
12. Douthwaite S, Hansen LH, Mauvais P. Macrolide-ketolide inhibition of MLS-resistant ribosomes is improved by alternative drug interaction with domain II of 23SrRNA. Mol Microbiol 2000;36:183-93.
13. National Committee for Clinical Laboratory Standards: Performance Standards for Antimicrobial Susceptibility Testing. Eleventh Informational Supplement; M 100-S 11. NCCLS 2001, Villanova, PA.
14. Marchese A, Schito GC. Resistance patterns of lower respiratory tract pathogens in Europe. Int J Antimicrob Agents 2000;16:S25-9.
15. Kozlov RS, Bogdanovitch TM, Appelbaum PC, Ednie L, Stratchounski LS, Jacobs MR, et al. Antistreptococcal activity of telithromycin compared with seven other drugs in relation to macrolide resistance mechanisms in Russia. Antimicrob Agents Chemother 2002;46:2963-8.
16. Ioannidou S, Tassios PT, Zachariadou L, Salem Z, Kanelopoulou M, Kanavaki S, et al. In vitro activity of telithromycin (HMR 3647) against Greek Streptococcus pyogenes and Streptococcus pneumoniae clinical isolates with different macrolide susceptibilities. Clin Microbiol Infect 2003;9:704-7.
17. Shackcloth J, Williams L, Farrell DJ. Streptococcus pneumoniae and Streptococcus pyogenes isolated from a paediatric population in Great Britain and Ireland: in vitro activity of telithromycin versus comparators. J Infect 2004;48:229-35.
18. Bozdogan B, Clark C, Bryskier A, Jacobs MR, Appelbaum PC. Activities of HMR 3787 and RU 64399 compared with those of four other agents against Haemophilus influenzae and Haemophilus parainfluenzae. Antimicrob Agents Chemother 2003;47:405-7.
19. Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC. Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time kill assay. Antimicrob Agents Chemother 1998;42:3032-4.
20. Biedenbach DJ, Barrett MS, Jones RN. Comparative antimicrobial activity and time kill-curve investigation of novel ketolide antimicrobial agents (HMR 3004 and HMR 3647) tested against Haemophilus influenzae and Moraxella catarrhalis strains. Diagn Microbiol Infect Dis 1998;31:349-53.
21. Odenholt I, Löwdin E, Cars O. Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens. Antimicrob Agents Chemother 2001;45:23-9.
22. Boswell FJ, Andrews JM, Wise R. Pharmacodynamic properties of HMR 3647, a novel ketolide, on respiratory pathogens, enterococci and Bacteroides fragilis demonstrated by studies of time-kill kinetics and postantibiotic effect. J Antimicrob Chemother 1998;41:149-53.
23. Rodvold KA, Gotfried MH, Danziger LH, Servi RJ. Intrapulmonary steady state concentrations of clarithromycin and azithromycin in healthy adult volunteers. Antimicrob Agents Chemother 1997;41:1399-402.
24. Muller-Serieys C, Andrews J, Vacheron F, Cantalloube C. Tissue kinetics of telithromycin, the first ketolide antibacterial. J Antimicrob Chemother 2004;53:149-57.